{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:46:44Z","timestamp":1778633204902,"version":"3.51.4"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T00:00:00Z","timestamp":1405468800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0102221","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T17:38:50Z","timestamp":1405532330000},"page":"e102221","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias"],"prefix":"10.1371","volume":"9","author":[{"given":"Yunyi","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edison","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Piermarocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Paternostro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"S Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukaemia","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)","volume":"80","author":"CA Westbrook","year":"1992","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice","volume":"1990","author":"GQ Daley","year":"1990","journal-title":"Science"},{"key":"ref5","first-page":"751","article-title":"The molecular biology of chronic myeloid leukaemia","volume":"10","author":"JV Melo","year":"1996","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"M Talpaz","year":"2002","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"N von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0301-472X(02)00836-6","article-title":"In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia","volume":"30","author":"P La Rosee","year":"2002","journal-title":"Exp Hematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","article-title":"Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL\u2014Inhibition of P-glycoprotein function by 17-AAG","volume":"19","author":"A Radujkovic","year":"2005","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","article-title":"Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs","volume":"16","author":"AJ Tipping","year":"2002","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e29374","DOI":"10.1371\/journal.pone.0029374","article-title":"Statistical Properties and Robustness of Biological Controller-Target Networks","volume":"7","author":"JD Feala","year":"2012","journal-title":"PLoS ONE"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1535-7163.MCT-07-0548","article-title":"Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue","volume":"7","author":"SH Hwang","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"9722","DOI":"10.1158\/0008-5472.CAN-05-4602","article-title":"Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells","volume":"66","author":"H Wang","year":"2006","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"MJ Garnett","year":"2012","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-05-2282","article-title":"Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1\/2 inhibitors in Bcr\/abl+ leukemia cells sensitive and resistant to imatinib mesylate","volume":"12","author":"TK Nguyen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"LM Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"ref18","unstructured":"Schneider JJ, Kirkpatrick S, SpringerLink (Online service) (2006) Stochastic Optimization. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"ME Gorre","year":"2002","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1203\/01.PDR.0000153871.45184.19","article-title":"Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity","volume":"57","author":"LM Hawkins","year":"2005","journal-title":"Pediatr Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"T Skorski","year":"1997","journal-title":"EMBO J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"AB Raitano","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","article-title":"Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia","volume":"14","author":"J Kuroda","year":"2007","journal-title":"Cell Death Differ"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"C Tse","year":"2008","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/leu.2009.292","article-title":"Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia","volume":"24","author":"JE Lancet","year":"2010","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"DJ Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"J Kuroda","year":"2008","journal-title":"Br J Haematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"E Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"M Carroll","year":"1997","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"T Anastassiadis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"H Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1073\/pnas.0800823105","article-title":"Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm","volume":"105","author":"PK Wong","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e1000249","DOI":"10.1371\/journal.pcbi.1000249","article-title":"Search algorithms as a framework for the optimization of drug combinations","volume":"4","author":"D Calzolari","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1039\/B815225J","article-title":"Integrative systems control approach for reactivating Kaposi's sarcoma-associated herpesvirus (KSHV) with combinatory drugs","volume":"1","author":"CP Sun","year":"2009","journal-title":"Integr Biol (Camb)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ncomms1165","article-title":"An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells","volume":"2","author":"H Tsutsui","year":"2011","journal-title":"Nat Commun"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"C Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.2004.05.065","article-title":"American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays","volume":"22","author":"D Schrag","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e82859","DOI":"10.1371\/journal.pone.0082859","article-title":"Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia","volume":"8","author":"S Tiziani","year":"2013","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"VT Bicocca","year":"2012","journal-title":"Cancer Cell"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0102221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:53:22Z","timestamp":1746305602000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0102221"}},"subtitle":[],"editor":[{"given":"Kevin D.","family":"Bunting","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,16]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0102221","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,16]]}}}